PledPharma AB News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

31.01.19	Aladote®’s data has been selected for presentation at The International Liver Congress (GlobeNewswire)
17.01.19	PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium (GlobeNewswire)
10.01.19	First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma (GlobeNewswire)
24.12.18	PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote (GlobeNewswire)
13.12.18	PledPharma presents results from study on drug candidate Aladote® for paracetamol poisoning at a global toxicology conference (GlobeNewswire)
05.12.18	PledPharma prepares for listing on the Nasdaq Stockholm main market during 2019 (GlobeNewswire)
08.11.18	The first patient included in PledPharma’s global Phase III program for PledOx® (GlobeNewswire)
26.10.18	Nomination Committee appointed for the 2019 Annual General Meeting in PledPharma (GlobeNewswire)
23.10.18	Interim Report January-September 2018 (GlobeNewswire)
28.09.18	Study drug for the PledOx® global phase III program delivered (GlobeNewswire)
24.09.18	Pledpharma announces positive results from the Aladote® proof of principle study (GlobeNewswire)
22.08.18	Half-Year Report January-June 2018 (GlobeNewswire)
15.08.18	Delivery of study drug to the PledOx® phase III program is expected in September (GlobeNewswire)
25.06.18	PledPharma establishes a Scientific Advisory Board for the continued clinical development of Aladote® (GlobeNewswire)
25.06.18	Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US (GlobeNewswire)
13.06.18	Japanese Medical Agency (PMDA) supports the expansion of the Phase III program for PledOx® to include Japanese patients (GlobeNewswire)
14.05.18	PledPharma has completed the recruitment for the clinical trial with Aladote® (GlobeNewswire)
24.04.18	Interim Report January-March 2018 (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	546.00	4.52 %	K V
CieFinRichemont	135.95	1.72 %	K V
Holcim	90.28	1.19 %	K V
UBS Group	28.58	0.99 %	K V
Alcon	76.34	0.34 %	K V
Geberit	545.80	-0.37 %	K V
Swiss Life Hldg	686.00	-0.84 %	K V
Sika	229.90	-0.91 %	K V
Part Grp Hldg	1’283.00	-1.08 %	K V
Kuehne+Nagel Int	204.60	-2.99 %	K V